DEWB´s portfolio company NOXXON closes 37 mill. EUR financing round

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

investments/NOXXON Financing Round

Jena/Berlin (euro adhoc) - Jena/Berlin, May 3, 2007 - DEWB´s
portfolio company NOXXON Pharma AG (NOXXON), developer of mirror
image oligonucleotide therapeutics termed Spiegelmers®, announced
today the successful closing of a 37 million Euros (50 million US $)
series C round of financing. The main new investors were TVM
Capital, Sofinnova Partners, and Edmond de Rothschild Investment
Partners. As existing lead investor Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft AG participated in the round on an
under proportional basis and will hold after the first tranche a
share of 28.0 % and after final payment 20.7 %. FCP OP MEDICAL
BioHealth-Trends (advised by Medical Strategy) and the Dieckell
Group, as well as new investors Seventure, Dow Venture Capital (The
Dow Chemical Company), IBG Beteiligungsgesellschaft Sachsen-Anhalt
mbH, VC Fonds Berlin, and others joined the financing round to fund
the pre-clinical and clinical development of NOXXON´s lead products
in kidney disease and ophthalmology.

Bertram Köhler, Member of the Management Board of DEWB, commented:
"We are pleased to see our past engagement resulting in this
outstanding financing round with an international syndicate of
leading biotech investors. This forms a solid ground for the next
phase of growth of our portfolio company and increase in value by
becoming a major player in the next generation of improved
therapeutics after the antibody success."

"This impressive investment puts NOXXON in an excellent position to
move our lead compounds NOX-E36 for the treatment of lupus nephritis
and NOX-A12 for the treatment of diabetic retinopathy into the clinic
and through clinical proof of concept", stated NOXXON´s CEO and CSO
Dr. Sven Klussmann. "We are excited to drive these projects to the
next development phase and to demonstrate the potential of the
Spiegelmer technology. We feel honored to have received such strong
financial support from this elite group of investors and thank our
old and new investors for their trust and strategic input in the past
and as we move forward."

NOXXON´s lead compounds NOX-E36 and NOX-A12 are high potency
inhibitors that were generated with NOXXON´s proprietary Spiegelmer
technology. A third Spiegelmer, NOX-B11, was licensed to Pfizer Inc.
in 2006 and is developed for the treatment of obesity. Spiegelmers
are marked by their biostability and an extremely low potential for
toxic or immunogenic side effects. The funds raised in this series C
investment are allocated for the pre-clinical and clinical
development of NOXXON´s lead products and to generate novel
therapeutic leads in indications with an unmet medical need.

About NOXXON Pharma AG: Based on one of the biggest and best
protected patent portfolio in the industry, Berlin-based NOXXON
Pharma AG develops biostable aptamers, novel substances based on
mirror image nucleic acids. These so-called Spiegelmers® (the German
word "Spiegel" means mirror) are highly specific for the
pharmacologically relevant target for which they were selected.
Thanks to their structural characteristics, Spiegelmers® are
extremely resistant to degradation and not immunogenic - a new
generation of improved therapeutics. www.noxxon.net

About DEWB: Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft
AG (DEWB AG) is an investment company which specializes in young and
established medium-sized companies in the field of optical
technologies and sensor systems within the region of Germany, Austria
and Switzerland. We provide support for strong growth companies in
the form of sharehold-ers´ equity, comprehensive expertise in
corporate development and our sector network.

Our interdisciplinary team, with years of experience in the
acquisition, development and sale of investment holdings, possesses
commercial, legal and financing know-how. What sets it apart from the
rest is its well-developed technical understanding of the target
sectors. Since 1997 we have invested more than 300 million Euros in
52 companies and realized more than 400 million Euros through 32
exits, eight of which were in the form of IPOs.

The company´s registered offices are located in Jena, one of the most
successful technology and science regions in Germany, with a long
tradition in the field of optical technologies and one of the most
important European centres for Photonics.

end of announcement euro adhoc 03.05.2007 10:20:31
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Mirko Wäckerle
Vorstand
Tel.: +49 (0)3641 573 3600
E-Mail: ir@dewb-vc.com
www.dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Baden-Württembergische Wertpapierbörse / free trade
Bayerische Börse / free trade